共 12 条
[1]
[2]
[3]
[4]
The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis[J] Shinji Maeda;Yoshihito Hayami;Taio Naniwa;Ryuzo Ueda;Lazaros I. Sakkas International Journal of Rheumatology 2012,
[5]
The IL‐17 pathway as a major therapeutic target in autoimmune diseases[J] YanHu;FangShen;Natasha K.Crellin;WenjunOuyang Annals of the New York Academy of Sciences 2011,
[6]
Immunological aspect of cardiac remodeling: T lymphocyte subsets in inflammation-mediated cardiac fibrosis[J] Liu Wei Experimental and Molecular Pathology 2010,
[7]
Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial[J] M.Lebwohl;K.Papp;C.Han;B.Schenkel;N.Yeilding;Y.Wang;G.G.Krueger British Journal of Dermatology 2009,
[8]
Ustekinumab; a human interleukin 12/23 monoclonal antibody; for psoriatic arthritis: randomised; double-blind; placebo-controlled; crossover trial[J] Alice Gottlieb;Alan Menter;Alan Mendelsohn;Yaung-Kaung Shen;Shu Li;Cynthia Guzzo;Scott Fretzin;Rod Kunynetz;Arthur Kavanaugh The Lancet 2009,
[9]
Keratinocyte but Not Endothelial Cell-Specific Overexpression of Tie2 Leads to the Development of Psoriasis[J] Julie A. Wolfram;Doina Diaconu;Denise A. Hatala;Jessica Rastegar;Dorothy A. Knutsen;Abigail Lowther;David Askew;Anita C. Gilliam;Thomas S. McCormick;Nicole L. Ward The American Journal of Pathology 2009,
[10]
Interleukin‐1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin‐1 receptor antagonist–deficient mice[J] Marije I.Koenders;IsabelDevesa;Renoud J.Marijnissen;ShahlaAbdollahi‐Roodsaz;Annemieke M. H.Boots;BirgitteWalgreen;Franco E.di Padova;Martin J. H.Nicklin;Leo A. B.Joosten;Wim B.van den Berg Arthritis & Rheumatism 2008,

